<!DOCTYPE html>
<!-- This site was created with Wowchemy. https://www.wowchemy.com -->
<!-- Last Published: October 13, 2022 --><html lang="en-us" >


<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  
  
  
    <meta name="generator" content="Wowchemy 5.7.0 for Hugo" />
  

  
  












  
  










  







  
  
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
  

  
  
  
    
      
      <link rel="preload" as="style" href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;700&family=Roboto+Mono&family=Roboto:wght@400;700&display=swap">
      <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;700&family=Roboto+Mono&family=Roboto:wght@400;700&display=swap" media="print" onload="this.media='all'">
    
  

  
  

  
  
    
    <script src="/js/mathjax-config.js"></script>
  

  

  <link rel="stylesheet" href="/css/vendor-bundle.min.16f785cdb553c8c4431db6775122af35.css" media="print" onload="this.media='all'">

  
  
  
    
    
      <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/academicons@1.9.2/css/academicons.min.css" integrity="sha512-KlJCpRsLf+KKu2VQa5vmRuClRFjxc5lXO03ixZt82HZUk41+1I0bD8KBSA0fY290ayMfWYI9udIqeOWSu1/uZg==" crossorigin="anonymous" media="print" onload="this.media='all'">
    

    
    
    
    
      
      
    
    
    

    
    
    

    

    
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml.js" integrity="" crossorigin="anonymous" async></script>
      
    
      
      

      
      

      
    
      
      

      
      

      
    
  

  
  
  
  
  
  
  <link rel="stylesheet" href="/css/wowchemy.e5d7adca760216d3b7e28ea434e81f6f.css" />

  
  
  
  
  
  
  
    
    
    <link rel="stylesheet" href="/css/libs/chroma/github-light.min.css" title="hl-light" media="print" onload="this.media='all'" >
    <link rel="stylesheet" href="/css/libs/chroma/dracula.min.css" title="hl-dark" media="print" onload="this.media='all'" disabled>
  

  
  


























  
  
  






  <meta name="author" content="Alessio Crippa" />





  

<meta name="description" content="INTRODUCTION: The COVID-19 pandemic brought an urgent need to discover novel effective therapeutics for patients hospitalised with severe COVID-19. The Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis (ISPY COVID-19 trial) was designed and implemented in early 2020 to evaluate investigational agents rapidly and simultaneously on a phase 2 adaptive platform. This manuscript outlines the design, rationale, implementation and challenges of the ISPY COVID-19 trial during the first phase of trial activity from April 2020 until December 2021. METHODS AND ANALYSIS: The ISPY COVID-19 Trial is a multicentre open-label phase 2 platform trial in the USA designed to evaluate therapeutics that may have a large effect on improving outcomes from severe COVID-19. The ISPY COVID-19 Trial network includes academic and community hospitals with significant geographical diversity across the country. Enrolled patients are randomised to receive one of up to four investigational agents or a control and are evaluated for a family of two primary outcomes-time to recovery and mortality. The statistical design uses a Bayesian model with &#39;stopping&#39; and &#39;graduation&#39; criteria designed to efficiently discard ineffective therapies and graduate promising agents for definitive efficacy trials. Each investigational agent arm enrols to a maximum of 125 patients per arm and is compared with concurrent controls. As of December 2021, 11 investigational agent arms had been activated, and 8 arms were complete. Enrolment and adaptation of the trial design are ongoing. ETHICS AND DISSEMINATION: ISPY COVID-19 operates under a central institutional review board via Wake Forest School of Medicine IRB00066805. Data generated from this trial will be reported in peer-reviewed medical journals. TRIAL REGISTRATION NUMBER: NCT04488081." />



<link rel="alternate" hreflang="en-us" href="https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/publication/2022-06-06_i-spy_covid_adaptive/" />
<link rel="canonical" href="https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/publication/2022-06-06_i-spy_covid_adaptive/" />



  <link rel="manifest" href="/manifest.webmanifest" />



<link rel="icon" type="image/png" href="/media/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_32x32_fill_lanczos_center_3.png" />
<link rel="apple-touch-icon" type="image/png" href="/media/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_180x180_fill_lanczos_center_3.png" />

<meta name="theme-color" content="#1565c0" />










  
  






<meta property="twitter:card" content="summary" />

  <meta property="twitter:site" content="@wowchemy" />
  <meta property="twitter:creator" content="@wowchemy" />
<meta property="twitter:image" content="https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/media/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_3.png" />
<meta property="og:site_name" content="Alessio Crippa" />
<meta property="og:url" content="https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/publication/2022-06-06_i-spy_covid_adaptive/" />
<meta property="og:title" content="I-SPY COVID Adaptive Platform Trial for COVID-19 Acute Respiratory Failure: Rationale, Design and Operations | Alessio Crippa" />
<meta property="og:description" content="INTRODUCTION: The COVID-19 pandemic brought an urgent need to discover novel effective therapeutics for patients hospitalised with severe COVID-19. The Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis (ISPY COVID-19 trial) was designed and implemented in early 2020 to evaluate investigational agents rapidly and simultaneously on a phase 2 adaptive platform. This manuscript outlines the design, rationale, implementation and challenges of the ISPY COVID-19 trial during the first phase of trial activity from April 2020 until December 2021. METHODS AND ANALYSIS: The ISPY COVID-19 Trial is a multicentre open-label phase 2 platform trial in the USA designed to evaluate therapeutics that may have a large effect on improving outcomes from severe COVID-19. The ISPY COVID-19 Trial network includes academic and community hospitals with significant geographical diversity across the country. Enrolled patients are randomised to receive one of up to four investigational agents or a control and are evaluated for a family of two primary outcomes-time to recovery and mortality. The statistical design uses a Bayesian model with &#39;stopping&#39; and &#39;graduation&#39; criteria designed to efficiently discard ineffective therapies and graduate promising agents for definitive efficacy trials. Each investigational agent arm enrols to a maximum of 125 patients per arm and is compared with concurrent controls. As of December 2021, 11 investigational agent arms had been activated, and 8 arms were complete. Enrolment and adaptation of the trial design are ongoing. ETHICS AND DISSEMINATION: ISPY COVID-19 operates under a central institutional review board via Wake Forest School of Medicine IRB00066805. Data generated from this trial will be reported in peer-reviewed medical journals. TRIAL REGISTRATION NUMBER: NCT04488081." /><meta property="og:image" content="https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/media/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_3.png" /><meta property="og:locale" content="en-us" />

  
    <meta
      property="article:published_time"
      content="2022-06-06T00:00:00&#43;00:00"
    />
  
  
    <meta property="article:modified_time" content="2022-06-06T00:00:00&#43;00:00">
  






    









<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/publication/2022-06-06_i-spy_covid_adaptive/"
  },
  "headline": "I-SPY COVID Adaptive Platform Trial for COVID-19 Acute Respiratory Failure: Rationale, Design and Operations",
  
  "datePublished": "2022-06-06T00:00:00Z",
  "dateModified": "2022-06-06T00:00:00Z",
  
  "author": {
    "@type": "Person",
    "name": "Daniel Clark Files"
  },
  
  "publisher": {
    "@type": "Organization",
    "name": "Alessio Crippa",
    "logo": {
      "@type": "ImageObject",
      "url": "https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/media/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_192x192_fill_lanczos_center_3.png"
    }
  },
  "description": "INTRODUCTION: The COVID-19 pandemic brought an urgent need to discover novel effective therapeutics for patients hospitalised with severe COVID-19. The Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis (ISPY COVID-19 trial) was designed and implemented in early 2020 to evaluate investigational agents rapidly and simultaneously on a phase 2 adaptive platform. This manuscript outlines the design, rationale, implementation and challenges of the ISPY COVID-19 trial during the first phase of trial activity from April 2020 until December 2021. METHODS AND ANALYSIS: The ISPY COVID-19 Trial is a multicentre open-label phase 2 platform trial in the USA designed to evaluate therapeutics that may have a large effect on improving outcomes from severe COVID-19. The ISPY COVID-19 Trial network includes academic and community hospitals with significant geographical diversity across the country. Enrolled patients are randomised to receive one of up to four investigational agents or a control and are evaluated for a family of two primary outcomes-time to recovery and mortality. The statistical design uses a Bayesian model with 'stopping' and 'graduation' criteria designed to efficiently discard ineffective therapies and graduate promising agents for definitive efficacy trials. Each investigational agent arm enrols to a maximum of 125 patients per arm and is compared with concurrent controls. As of December 2021, 11 investigational agent arms had been activated, and 8 arms were complete. Enrolment and adaptation of the trial design are ongoing. ETHICS AND DISSEMINATION: ISPY COVID-19 operates under a central institutional review board via Wake Forest School of Medicine IRB00066805. Data generated from this trial will be reported in peer-reviewed medical journals. TRIAL REGISTRATION NUMBER: NCT04488081."
}
</script>

  

  




  
  
  

  
  

  


  
  <title>I-SPY COVID Adaptive Platform Trial for COVID-19 Acute Respiratory Failure: Rationale, Design and Operations | Alessio Crippa</title>

  
  
  
  











</head>


<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" class="page-wrapper   " data-wc-page-id="7206c00d845749e20859ac6a8f0833ef" >

  
  
  
  
  
  
  
  
  
  <script src="/js/wowchemy-init.min.ec9d49ca50e4b80bdb08f0417a28ed84.js"></script>

  


<aside class="search-modal" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#" aria-label="Close"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search" class="form-control"
        aria-label="Search...">
        
      </div>

      
      

      

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>



  <div class="page-header header--fixed">
    












<header>
  <nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
    <div class="container-xl">

      
      <div class="d-none d-lg-inline-flex">
        <a class="navbar-brand" href="/">Alessio Crippa</a>
      </div>
      

      
      <button type="button" class="navbar-toggler" data-toggle="collapse"
              data-target="#navbar-content" aria-controls="navbar-content" aria-expanded="false" aria-label="Toggle navigation">
      <span><i class="fas fa-bars"></i></span>
      </button>
      

      
      <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
        <a class="navbar-brand" href="/">Alessio Crippa</a>
      </div>
      

      
      
      <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

        
        <ul class="navbar-nav d-md-inline-flex">
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#about"><span>Home</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#projects"><span>Projects</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#publications"><span>Publications</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#talks"><span>Talks</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#teaching"><span>Teaching</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#software"><span>Software</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#webapp"><span>WebApp</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#contact"><span>Contact</span></a>
          </li>

          
          

        

          
        </ul>
      </div>

      <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">

        
        
          
            
            <li class="nav-item d-none d-lg-inline-flex">
              <a class="nav-link" href="https://twitter.com/AlessioCrippa" data-toggle="tooltip" data-placement="bottom" title="Follow me on Twitter" target="_blank" rel="noopener" aria-label="Follow me on Twitter">
                <i class="fab fa-twitter" aria-hidden="true"></i>
              </a>
            </li>
          
        

        
        
        
        <li class="nav-item">
          <a class="nav-link js-search" href="#" aria-label="Search"><i class="fas fa-search" aria-hidden="true"></i></a>
        </li>
        

        
        
        
        <li class="nav-item dropdown theme-dropdown">
          <a href="#" class="nav-link" data-toggle="dropdown" aria-haspopup="true" aria-label="Display preferences">
            <i class="fas fa-moon" aria-hidden="true"></i>
          </a>
          <div class="dropdown-menu">
            <a href="#" class="dropdown-item js-set-theme-light">
              <span>Light</span>
            </a>
            <a href="#" class="dropdown-item js-set-theme-dark">
              <span>Dark</span>
            </a>
            <a href="#" class="dropdown-item js-set-theme-auto">
              <span>Automatic</span>
            </a>
          </div>
        </li>
        

        
        

      </ul>

    </div>
  </nav>
</header>


  </div>

  <div class="page-body">
    
    
    

    








<div class="pub">

  













  

  
  
  
<div class="article-container pt-3">
  <h1>I-SPY COVID Adaptive Platform Trial for COVID-19 Acute Respiratory Failure: Rationale, Design and Operations</h1>

  

  
    


<div class="article-metadata">

  
  
  
  
  <div>
    

  <span >
      Daniel Clark Files</span>, <span >
      Michael A. Matthay</span>, <span >
      Carolyn S. Calfee</span>, <span >
      Neil R. Aggarwal</span>, <span >
      Adam L. Asare</span>, <span >
      Jeremy R. Beitler</span>, <span >
      Paul A. Berger</span>, <span >
      Ellen L. Burnham</span>, <span >
      George Cimino</span>, <span >
      Melissa H. Coleman</span>, <span >
      Alessio Crippa</span>, <span >
      Andrea Discacciati</span>, <span >
      Sheetal Gandotra</span>, <span >
      Kevin W. Gibbs</span>, <span >
      Paul T. Henderson</span>, <span >
      Caroline A. G. Ittner</span>, <span >
      Alejandra Jauregui</span>, <span >
      Kashif T. Khan</span>, <span >
      Jonathan L. Koff</span>, <span >
      Julie Lang</span>, <span >
      Mary LaRose</span>, <span >
      Joe Levitt</span>, <span >
      Ruixiao Lu</span>, <span >
      Jeffrey D. McKeehan</span>, <span >
      Nuala J. Meyer</span>, <span >
      Derek W. Russell</span>, <span >
      Karl W. Thomas</span>, <span >
      Martin Eklund</span>, <span >
      Laura J. Esserman</span>, <span >
      Kathleen D. Liu</span>, <span >
      {ISPY COVID Adaptive Platform Trial Network}</span>, <span >
      {undefined}</span>
  </div>
  
  

  
  <span class="article-date">
    
    
      
    
    June, 2022
  </span>
  

  

  

  
  
  
  

  
  

</div>

    





  
</div>



  <div class="article-container">

    
    <h3>Abstract</h3>
    <p class="pub-abstract">INTRODUCTION: The COVID-19 pandemic brought an urgent need to discover novel effective therapeutics for patients hospitalised with severe COVID-19. The Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis (ISPY COVID-19 trial) was designed and implemented in early 2020 to evaluate investigational agents rapidly and simultaneously on a phase 2 adaptive platform. This manuscript outlines the design, rationale, implementation and challenges of the ISPY COVID-19 trial during the first phase of trial activity from April 2020 until December 2021. METHODS AND ANALYSIS: The ISPY COVID-19 Trial is a multicentre open-label phase 2 platform trial in the USA designed to evaluate therapeutics that may have a large effect on improving outcomes from severe COVID-19. The ISPY COVID-19 Trial network includes academic and community hospitals with significant geographical diversity across the country. Enrolled patients are randomised to receive one of up to four investigational agents or a control and are evaluated for a family of two primary outcomes-time to recovery and mortality. The statistical design uses a Bayesian model with &lsquo;stopping&rsquo; and &lsquo;graduation&rsquo; criteria designed to efficiently discard ineffective therapies and graduate promising agents for definitive efficacy trials. Each investigational agent arm enrols to a maximum of 125 patients per arm and is compared with concurrent controls. As of December 2021, 11 investigational agent arms had been activated, and 8 arms were complete. Enrolment and adaptation of the trial design are ongoing. ETHICS AND DISSEMINATION: ISPY COVID-19 operates under a central institutional review board via Wake Forest School of Medicine IRB00066805. Data generated from this trial will be reported in peer-reviewed medical journals. TRIAL REGISTRATION NUMBER: NCT04488081.</p>
    

    
    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            <a href="/publication/#2">
              Journal article
            </a>
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Publication</div>
          <div class="col-12 col-md-9">BMJ open, 12Article (6) e060664. <a href="https://doi.org/10.1136/bmjopen-2021-060664" target="_blank" rel="noopener">https://doi.org/10.1136/bmjopen-2021-060664</a>. ISSN: 2044-6055</div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    <div class="space-below"></div>

    <div class="article-style"></div>

    





<div class="article-tags">
  
  <a class="badge badge-light" href="/tag/adult-intensive-critical-care/">adult intensive &amp; critical care</a>
  
  <a class="badge badge-light" href="/tag/bayes-theorem/">Bayes Theorem</a>
  
  <a class="badge badge-light" href="/tag/clinical-trials/">Clinical trials</a>
  
  <a class="badge badge-light" href="/tag/covid-19/">COVID-19</a>
  
  <a class="badge badge-light" href="/tag/humans/">Humans</a>
  
  <a class="badge badge-light" href="/tag/pandemics/">Pandemics</a>
  
  <a class="badge badge-light" href="/tag/respiratory-distress-syndrome/">Respiratory Distress Syndrome</a>
  
  <a class="badge badge-light" href="/tag/respiratory-insufficiency/">Respiratory Insufficiency</a>
  
  <a class="badge badge-light" href="/tag/sars-cov-2/">SARS-CoV-2</a>
  
  <a class="badge badge-light" href="/tag/treatment-outcome/">Treatment Outcome</a>
  
</div>



<div class="share-box">
  <ul class="share">
    
      
      
      
        
      
      
      
      
      
      
      
      <li>
        <a href="https://twitter.com/intent/tweet?url=https%3A%2F%2F6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app%2Fpublication%2F2022-06-06_i-spy_covid_adaptive%2F&amp;text=I-SPY&#43;COVID&#43;Adaptive&#43;Platform&#43;Trial&#43;for&#43;COVID-19&#43;Acute&#43;Respiratory&#43;Failure%3A&#43;Rationale%2C&#43;Design&#43;and&#43;Operations" target="_blank" rel="noopener" class="share-btn-twitter" aria-label="twitter">
          <i class="fab fa-twitter"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      
      
      
      
      <li>
        <a href="https://www.facebook.com/sharer.php?u=https%3A%2F%2F6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app%2Fpublication%2F2022-06-06_i-spy_covid_adaptive%2F&amp;t=I-SPY&#43;COVID&#43;Adaptive&#43;Platform&#43;Trial&#43;for&#43;COVID-19&#43;Acute&#43;Respiratory&#43;Failure%3A&#43;Rationale%2C&#43;Design&#43;and&#43;Operations" target="_blank" rel="noopener" class="share-btn-facebook" aria-label="facebook">
          <i class="fab fa-facebook"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      
      
      
      
        
      
      <li>
        <a href="mailto:?subject=I-SPY%20COVID%20Adaptive%20Platform%20Trial%20for%20COVID-19%20Acute%20Respiratory%20Failure%3A%20Rationale%2C%20Design%20and%20Operations&amp;body=https%3A%2F%2F6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app%2Fpublication%2F2022-06-06_i-spy_covid_adaptive%2F" target="_blank" rel="noopener" class="share-btn-email" aria-label="envelope">
          <i class="fas fa-envelope"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      
      
      
      
      <li>
        <a href="https://www.linkedin.com/shareArticle?url=https%3A%2F%2F6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app%2Fpublication%2F2022-06-06_i-spy_covid_adaptive%2F&amp;title=I-SPY&#43;COVID&#43;Adaptive&#43;Platform&#43;Trial&#43;for&#43;COVID-19&#43;Acute&#43;Respiratory&#43;Failure%3A&#43;Rationale%2C&#43;Design&#43;and&#43;Operations" target="_blank" rel="noopener" class="share-btn-linkedin" aria-label="linkedin-in">
          <i class="fab fa-linkedin-in"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      
      
      
      
      <li>
        <a href="whatsapp://send?text=I-SPY&#43;COVID&#43;Adaptive&#43;Platform&#43;Trial&#43;for&#43;COVID-19&#43;Acute&#43;Respiratory&#43;Failure%3A&#43;Rationale%2C&#43;Design&#43;and&#43;Operations%20https%3A%2F%2F6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app%2Fpublication%2F2022-06-06_i-spy_covid_adaptive%2F" target="_blank" rel="noopener" class="share-btn-whatsapp" aria-label="whatsapp">
          <i class="fab fa-whatsapp"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      
      
      
      
      <li>
        <a href="https://service.weibo.com/share/share.php?url=https%3A%2F%2F6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app%2Fpublication%2F2022-06-06_i-spy_covid_adaptive%2F&amp;title=I-SPY&#43;COVID&#43;Adaptive&#43;Platform&#43;Trial&#43;for&#43;COVID-19&#43;Acute&#43;Respiratory&#43;Failure%3A&#43;Rationale%2C&#43;Design&#43;and&#43;Operations" target="_blank" rel="noopener" class="share-btn-weibo" aria-label="weibo">
          <i class="fab fa-weibo"></i>
        </a>
      </li>
    
  </ul>
</div>











  
  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
















  </div>
</div>
  </div>

  <div class="page-footer">
    
    
    <div class="container">
      <footer class="site-footer">

  












  
  
  
  
  













  
  
  

  
  
    
  
  
    
  

  

  
  <p class="powered-by copyright-license-text">
    © 2022 Me. This work is licensed under <a href="https://creativecommons.org/licenses/by-nc-nd/4.0" rel="noopener noreferrer" target="_blank">CC BY NC ND 4.0</a>
  </p>
  

  <p class="powered-by footer-license-icons">
    <a href="https://creativecommons.org/licenses/by-nc-nd/4.0" rel="noopener noreferrer" target="_blank" aria-label="Creative Commons">
      <i class="fab fa-creative-commons fa-2x" aria-hidden="true"></i>
      <i class="fab fa-creative-commons-by fa-2x" aria-hidden="true"></i>
      
        <i class="fab fa-creative-commons-nc fa-2x" aria-hidden="true"></i>
      
      
        <i class="fab fa-creative-commons-nd fa-2x" aria-hidden="true"></i>
      
    </a>
  </p>





  <p class="powered-by">
    
    
    
      
      
      
      
      
      
      Published with <a href="https://wowchemy.com/?utm_campaign=poweredby" target="_blank" rel="noopener">Wowchemy</a> — the free, <a href="https://github.com/wowchemy/wowchemy-hugo-themes" target="_blank" rel="noopener">open source</a> website builder that empowers creators.
    
  </p>
</footer>

    </div>
    
  </div>

  


<script src="/js/vendor-bundle.min.d26509351aa0ff874abbee824e982e9b.js"></script>




  

  
  

  













  
  <script id="search-hit-fuse-template" type="text/x-template">
    <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
    </div>
  </script>
  
    <script src="https://cdn.jsdelivr.net/gh/krisk/Fuse@v3.2.1/dist/fuse.min.js" integrity="sha512-o38bmzBGX+hD3JHWUFCDA09btWaqrNmoJ3RXLlrysA7PP01Kgs4UlE4MhelE1v5dJR3+cxlR4qQlotsW7jKsnw==" crossorigin="anonymous"></script>
    <script src="https://cdn.jsdelivr.net/gh/julmot/mark.js@8.11.1/dist/jquery.mark.min.js" integrity="sha512-mhbv5DqBMgrWL+32MmsDOt/OAvqr/cHimk6B8y/bx/xS88MVkYGPiVv2ixKVrkywF2qHplNRUvFsAHUdxZ3Krg==" crossorigin="anonymous"></script>
  












  
  
  
  
  
  
  







<script id="page-data" type="application/json">{"use_headroom":true}</script>



  <script src="/js/wowchemy-headroom.db4755770454eb63685f8de785c0a172.js" type="module"></script>









  
  


<script src="/en/js/wowchemy.min.e8ee06ba8371980ffde659871dd593b0.js"></script>







  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        
        <pre><code></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>


  <script src="/js/wowchemy-publication.68f8d7090562ca65fc6d3cb3f8f2d2cb.js" type="module"></script>


















</body>
</html>
